Compare SGI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGI | NBIX |
|---|---|---|
| Founded | 1846 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.5B |
| IPO Year | 2003 | 1996 |
| Metric | SGI | NBIX |
|---|---|---|
| Price | $70.01 | $155.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $97.88 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.01 | ★ 3.30 |
| Revenue | ★ $2,754,400,000.00 | $161,626,000.00 |
| Revenue This Year | $7.30 | $24.73 |
| Revenue Next Year | $4.99 | $13.14 |
| P/E Ratio | $69.18 | ★ $47.16 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $60.39 | $122.14 |
| 52 Week High | $98.56 | $186.12 |
| Indicator | SGI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 44.49 |
| Support Level | $69.30 | $152.67 |
| Resistance Level | $70.54 | $161.29 |
| Average True Range (ATR) | 2.16 | 3.81 |
| MACD | 1.01 | 0.77 |
| Stochastic Oscillator | 95.58 | 47.31 |
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses Mattress Firm, Tempur Sealy North America and Tempur Sealy International. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.